

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

SCT Multiple Myeloma Meeting - 2/25/2026 – 78468-71399

Date: February 25, 2026

Time: 8:00 AM-9:00 AM

UH Cleveland Medical Center

Timothy O'brien, MD
Louis Stokes Cleveland VAMC

Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Review recent updates to pivotal MM studies, particularly CAR T studies, presented at the International Myeloma Society meeting.
- 2 Identify key mechanisms of BCMA CAR T resistance
- 3 Apply recent trial data to inform the clinical application of the two FDA-approved BCMA CAR T cells-ide cel and ciltacel.

Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Lauren Brister, MSN, APRN-CNP	Other Planning Committee Member	Nothing to disclose - 07/03/2025
Brenda Cooper, MD	Course Director	Nothing to disclose - 06/24/2025
Molly Gallogly, MD, PhD	Other Planning Committee Member	Consulting Fee-Incyte Consulting Fee-Techspert Speakers Bureau-Lilly Honoraria-MJH Life Sciences Consulting Fee-Citrus Health Group (Relationship has

		ended) Consulting Fee-The Dedham Group (Relationship has ended) - 06/09/2025
James J Ignatz-Hoover , MD, PhD	Other Planning Committee Member	Speakers Bureau-Sanofi-Aventis - 06/05/2025
Leland Metheny, MD	Other Planning Committee Member	Speakers Bureau-Incyte Speakers Bureau-Taiho Advisor-Bristol-Myers Squibb (Relationship has ended) Advisor-Gamida - 07/23/2025
Timothy O'Brien, MD	Faculty	Nothing to disclose - 06/05/2025
Frank Oley, PharmD	Other Planning Committee Member	Nothing to disclose - 04/24/2025
Benjamin Tomlinson, MD	Other Planning Committee Member	Advisor-Bristol-Myers Squib Aventis (Relationship has ended) - 07/09/2025
Koen van Besien, MD, PhD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds- Hemogenyx Stocks or stock options, excluding diversified mutual funds- Avertix Advisor-autolus Advisor-ADC Therapeutics Advisor-intellia (Relationship has ended) Advisor-morphosys (Relationship has ended) Advisor-crispr (Relationship has ended) Advisor-incyte (Relationship has ended) Advisor-adbio - 07/31/2025